204 related articles for article (PubMed ID: 27830541)
1. Achievement of disease control with donor-derived EB virus-specific cytotoxic T cells after allogeneic peripheral blood stem cell transplantation for aggressive NK-cell leukemia.
Haji S; Shiratsuchi M; Matsushima T; Takamatsu A; Tsuda M; Tsukamoto Y; Tanaka E; Ohno H; Fujioka E; Ishikawa Y; Imadome KI; Ogawa Y
Int J Hematol; 2017 Apr; 105(4):540-544. PubMed ID: 27830541
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel CCDC22 mutation in a patient with severe Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and aggressive natural killer cell leukemia.
Yamashita Y; Nishikawa A; Iwahashi Y; Fujimoto M; Sasaki I; Mishima H; Kinoshita A; Hemmi H; Kanazawa N; Ohshima K; Imadome KI; Murata SI; Yoshiura KI; Kaisho T; Sonoki T; Tamura S
Int J Hematol; 2019 Jun; 109(6):744-750. PubMed ID: 30706328
[TBL] [Abstract][Full Text] [Related]
3. A probable identical Epstein-Barr virus clone-positive composite lymphoma with aggressive natural killer-cell leukemia and cytotoxic T-cell lymphoma.
Sugimoto KJ; Shimada A; Wakabayashi M; Imai H; Sekiguchi Y; Nakamura N; Sawada T; Ota Y; Takeuchi K; Ito Y; Kimura H; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2014; 7(1):411-7. PubMed ID: 24427365
[TBL] [Abstract][Full Text] [Related]
4. Successful Treatment of Pediatric Epstein-Barr Virus-positive Aggressive Natural Killer-Cell Leukemia.
Kim BK; Hong KT; Kang HJ; An HY; Choi JY; Hong CR; Park KD; Lee DS; Shin HY
J Pediatr Hematol Oncol; 2019 Jul; 41(5):e336-e337. PubMed ID: 29889803
[TBL] [Abstract][Full Text] [Related]
5. Successful allogeneic hematopoietic stem cell transplantation for aggressive NK cell leukemia.
Ichikawa S; Fukuhara N; Yamamoto J; Suzuki M; Nakajima S; Okitsu Y; Kohata K; Onishi Y; Ishizawa K; Kameoka J; Harigae H
Intern Med; 2010; 49(17):1907-10. PubMed ID: 20823655
[TBL] [Abstract][Full Text] [Related]
6. [Chronic active Epstein-Barr virus infection with marked pericardial effusion successfully treated with allogeneic peripheral blood stem cell transplantation].
Matsui S; Takeda Y; Isshiki Y; Yamazaki A; Nakao S; Takaishi K; Nagao Y; Hasegawa N; Togasaki E; Shimizu R; Kawajiri C; Sakai S; Mimura N; Takeuchi M; Ohwada C; Sakaida E; Iseki T; Imadome K; Nakaseko C
Rinsho Ketsueki; 2016 May; 57(5):624-9. PubMed ID: 27263789
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
Sato E; Ohga S; Kuroda H; Yoshiba F; Nishimura M; Nagasawa M; Inoue M; Kawa K
Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr Virus-positive T-cell Lymphoproliferative Disease Following Umbilical Cord Blood Transplantation for Acute Myeloid Leukemia.
Yui S; Yamaguchi H; Imadome K; Arai A; Takahashi M; Ohashi R; Tamai H; Moriya K; Nakayama K; Shimizu A; Inokuchi K
J Nippon Med Sch; 2016; 83(1):35-42. PubMed ID: 26960588
[TBL] [Abstract][Full Text] [Related]
9. In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
Bollard CM; Gottschalk S; Huls MH; Molldrem J; Przepiorka D; Rooney CM; Heslop HE
Leuk Lymphoma; 2006 May; 47(5):837-42. PubMed ID: 16753867
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of Epstein-Barr virus-associated natural killer cell large granular lymphocytic leukaemia using allogeneic peripheral blood stem cell transplantation.
Takami A; Nakao S; Yachie A; Kasahara Y; Okumura H; Miura Y; Sugimori N; Zeng W; Wang H; Kotani T; Shiobara S; Matsuda T
Bone Marrow Transplant; 1998 Jun; 21(12):1279-82. PubMed ID: 9674865
[TBL] [Abstract][Full Text] [Related]
11. Favorable outcome in a child with EBV-negative aggressive NK cell leukemia.
Park JA; Jun KR; Nam SH; Ghim TT
Int J Hematol; 2013 May; 97(5):673-6. PubMed ID: 23550023
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.
Haque T; Wilkie GM; Taylor C; Amlot PL; Murad P; Iley A; Dombagoda D; Britton KM; Swerdlow AJ; Crawford DH
Lancet; 2002 Aug; 360(9331):436-42. PubMed ID: 12241714
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection.
Fujii N; Takenaka K; Hiraki A; Maeda Y; Ikeda K; Shinagawa K; Ashiba A; Munemasa M; Sunami K; Hiramatsu Y; Ishimaru F; Niiya K; Yoshino T; Harada M
Bone Marrow Transplant; 2000 Oct; 26(7):805-8. PubMed ID: 11042666
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological analysis of the age-related differences in patients with Epstein-Barr virus (EBV)-associated extranasal natural killer (NK)/T-cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection-associated lymphoproliferative disorders.
Takahashi E; Ohshima K; Kimura H; Hara K; Suzuki R; Kawa K; Eimoto T; Nakamura S;
Histopathology; 2011 Oct; 59(4):660-71. PubMed ID: 22014047
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
Leen AM; Christin A; Myers GD; Liu H; Cruz CR; Hanley PJ; Kennedy-Nasser AA; Leung KS; Gee AP; Krance RA; Brenner MK; Heslop HE; Rooney CM; Bollard CM
Blood; 2009 Nov; 114(19):4283-92. PubMed ID: 19700662
[TBL] [Abstract][Full Text] [Related]
16. A case series of CAEBV of children and young adults treated with reduced-intensity conditioning and allogeneic bone marrow transplantation: a single-center study.
Watanabe Y; Sasahara Y; Satoh M; Looi CY; Katayama S; Suzuki T; Suzuki N; Ouchi M; Horino S; Moriya K; Nanjyo Y; Onuma M; Kitazawa H; Irie M; Niizuma H; Uchiyama T; Rikiishi T; Kumaki S; Minegishi M; Wada T; Yachie A; Tsuchiya S; Kure S
Eur J Haematol; 2013 Sep; 91(3):242-248. PubMed ID: 23734904
[TBL] [Abstract][Full Text] [Related]
17. Complete resolution of severe chronic active Epstein-Barr virus infection by cultured, activated donor T lymphocyte infusion after nonmyeloablative stem cells allografting.
Yoshiba F; Hagihara M; Tazume K; Ogawa Y; Kishi K; Higuchi A; Kato S; Hotta T
Bone Marrow Transplant; 2003 Jul; 32(1):107-10. PubMed ID: 12815486
[TBL] [Abstract][Full Text] [Related]
18. Aggressive natural killer cell leukemia: is Epstein-Barr virus negativity an indicator of a favorable prognosis?
Ko YH; Park S; Kim K; Kim SJ; Kim WS
Acta Haematol; 2008; 120(4):199-206. PubMed ID: 19153474
[TBL] [Abstract][Full Text] [Related]
19. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease.
Okamura T; Kishimoto T; Inoue M; Honda M; Yamashita N; Wakiguchi H; Yagita M; Hosoi G; Sako M; Yasui M; Yagi K; Kawa K
Bone Marrow Transplant; 2003 Jan; 31(2):105-11. PubMed ID: 12621491
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein-Barr virus (CAEBV) infection with allogeneic bone marrow transplantation.
Ebihara Y; Manabe A; Tanaka R; Yoshimasu T; Ishikawa K; Iseki T; Hayakawa J; Maeda M; Asano S; Tsuji K
Bone Marrow Transplant; 2003 Jun; 31(12):1169-71. PubMed ID: 12796798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
